ClinicalTrials.gg
CompletedNCT00430495AUGUST IUpdated Feb 17, 2016Results posted

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

A Phase 2 interventional study of Atacicept and Atacicept in Rheumatoid Arthritis, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
247th of 771
256 · median 120
Started
2006
with 34 others
Phase 2
215 of 975
12 open now
Registered
149th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 247th largest by enrollment of the 771 interventional ones that give a count, is one of 35 that started in 2006, is one of 215 in phase 2, and was the 149th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • atacicept
  • arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic criteria with a disease history of at least one year
  2. Male or female greater than or equal to (>=)18-years of age at time of
  3. Active RA as defined by:

    • >=8 swollen joints (66-joint count),
    • >=8 tender joints (68-joint count), and
    • C-reactive protein (CRP) >=10 milligram per liter (mg/L) (central laboratory) and/or erythrocyte sedimentation rate (ESR) >= to 28 millimeter per hour (mm/h)
  4. Failure of at least one TNFa antagonist therapy (previously or at the time of screening) as specified in the protocol
  5. Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  1. Any condition, including laboratory findings or findings in the medical history or pre-trial assessments, that in the opinion of the Investigator constitutes a risk or a for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation
  2. Treatment with biologics aiming at B cell modulation such as rituximab or belimumab within 2 years before study Day 1
  3. Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab within 3 months before study Day 1
  4. Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab (Remicade) or adalimumab (Humira) within 60 days before study Day 1
  5. Participation in any interventional clinical trial with an unapproved therapy within the 3 months before the start of this study (or within 5 half-lives of the investigated compound before study Day 1, whichever is longer)
  6. Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Atacicept 25 mg

    Drug: Atacicept

  • Experimental
    Atacicept 75 mg

    Drug: Atacicept

  • Experimental
    Atacicept 150 mg

    Drug: Atacicept

  • Placebo comparator
    Placebo

    Drug: Placebo matched to atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26

    ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26

    ACR50-CRP response is defined as \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

  2. Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26

    ACR70-CRP response is defined as \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

  3. Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 26

    DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100-millimeter (mm) visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

    Time frame: Week 26

  4. Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 26

    DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

    Time frame: Week 26

  5. Percentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 26

    The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range is 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Percentage of participants achieving improvement in HAQ-DI of at least 0.3 from baseline at Week 26 was reported.

    Time frame: Week 26

  6. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 26

    The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was \<=5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.

    Time frame: Week 26

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

    Time frame: Baseline up to Week 38

07

Results

Posted Feb 17, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Started64666264
Treated62666264
Completed50594960
Not completed147134
Withdrew: Adverse event2320
Withdrew: Death0010
Withdrew: Lost to follow-up0140
Withdrew: Protocol violation1010
Withdrew: Disease progression1100
Withdrew: Other8254
Withdrew: Randomized but not treated2000

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26

ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 2629.030.327.439.1
SecondaryPercentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26

ACR50-CRP response is defined as \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 266.513.611.310.9
SecondaryPercentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26

ACR70-CRP response is defined as \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 260.06.14.80.0
SecondaryPercentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 26

DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100-millimeter (mm) visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of Less Than or Equal to (<=) 3.2 at Week 269.7 ± 0.9510.6 ± 0.849.7 ± 0.8812.5 ± 0.84
SecondaryPercentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 26

DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) of <=2.6 at Week 261.66.14.84.7
SecondaryPercentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 26

The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range is 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Percentage of participants achieving improvement in HAQ-DI of at least 0.3 from baseline at Week 26 was reported.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants Achieving Improvement in Health Assessment Questionnaire Disability Index (HAQ-DI) of at Least 0.3 From Baseline at Week 2647.448.855.937.5
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 26

The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was \<=5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 26
percentage of participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 2641.931.835.553.1
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

Time frame:
Baseline up to Week 38
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
AEs41494246
SAEs3985

Adverse events

Collected over Baseline up to Week 38. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/62 (4.8%)15/62 (24.2%)
Atacicept 25 mg—9/66 (13.6%)25/66 (37.9%)
Atacicept 75 mg—8/62 (12.9%)16/62 (25.8%)
Atacicept 150 mg—5/64 (7.8%)26/64 (40.6%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/622/662/620/64
Hip fractureInjury, poisoning and procedural complications0/620/662/620/64
Back painMusculoskeletal and connective tissue disorders1/620/660/620/64
OsteonecrosisMusculoskeletal and connective tissue disorders0/620/661/620/64
Femur fractureInjury, poisoning and procedural complications1/621/660/620/64
Acute myocardial infarctionCardiac disorders0/620/661/620/64
Angina pectorisCardiac disorders0/620/661/620/64
Cardio-respiratory arrestCardiac disorders0/620/661/620/64
Basedow's diseaseEndocrine disorders1/620/660/620/64
MigraineNervous system disorders1/620/660/620/64
Most frequent other events
Most frequent other events
EventPlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mg
HeadacheNervous system disorders4/6212/665/623/64
Upper respiratory tract infectionInfections and infestations4/623/660/628/64
DiarrhoeaGastrointestinal disorders1/624/666/625/64
HypertensionVascular disorders5/623/663/622/64
Urinary tract infectionInfections and infestations3/624/663/625/64
NauseaGastrointestinal disorders1/625/664/621/64
NasopharyngitisInfections and infestations1/623/661/624/64
Iron deficiency anaemiaBlood and lymphatic system disorders0/621/660/624/64
ConstipationGastrointestinal disorders1/624/661/622/64

Baseline characteristics

Intention-to-treat (ITT) population included all randomized participants who received at least one treatment dose.

Age, Continuous
Age, Continuous(years)PlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mgTotal
Mean53.1 ± 12.553.4 ± 13.155.3 ± 12.053.5 ± 10.153.8 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtacicept 25 mgAtacicept 75 mgAtacicept 150 mgTotal
Female51545353211
Male111291143
08

Study locations

2 sites
  • EMD Serono
    Rockland, Massachusetts 02370, United States
  • Merck/Serono
    Canada, Canada
09

References and documents

Publications

  • Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011 Jul;63(7):1793-803. doi: 10.1002/art.30373. PubMed 21452293 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2007
First posted
Feb 2, 2007
Start
Dec 2006
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Feb 17, 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00430495
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 2, 2007
Start date
Dec 2006
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Feb 17, 2016
Last update
Feb 17, 2016

Study contacts

Medical Responsible
study director · EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion